Influence of age and gender on the pharmacodynamic parameters of rocuronium during total intravenous anesthesia

Biomedical Papers

Volumn 155, Issue 4, 2011, Pages 233-240

  Adamus, Milan ^a   Hrabalek, Lumir ^a   Wanek, Tomas ^a   Gabrhelik, Tomas ^a   Zapletalova, Jana ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Age; Gender; Neuromuscular blockade; Rocuronium

Indexed keywords

ANDROSTANE DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM;

ADULT; AGED; AGING; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; INTRAVENOUS ANESTHESIA; MALE; METABOLISM; MIDDLE AGED; NEUROMUSCULAR BLOCKING; SEXUAL DEVELOPMENT;

ADULT; AGED; AGING; ANDROSTANOLS; ANESTHESIA, INTRAVENOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; SEX CHARACTERISTICS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84255192994     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2011.050      Document Type: Article

References (37)

1. Herold I. Muscle relaxants in anesthesiology and intensive caremedicine [in Czech]. 1st ed. Prague: Maxdorf; 2004.
2. Lee CL, Katz RL. Clinical implications of new neuromuscularconcepts and agents: So long, neostigmine! So long, sux! J CritCare 2009;24:43-9.
3. Lee C. Goodbye Suxamethonium! Anaesthesia 2009;64(Suppl1):73-81.
4. Mencke T, Soltesz S, Grundmann U, Bauer M, Schlaich N, LarsenR, Fuchs-Buder T. Time course of neuromuscular blockade afterrocuronium. A comparison between women and men. Anaesthesist 2000;49:609-12.
5. Adamus M, Gabrhelik T, Marek O. Influence of gender on thecourse of neuromuscular block following a single bolus dose ofcisatracurium or rocuronium. Eur J Anaesthesiol 2008;25:589-95.
6. Arain S, Kern S, Ficke D, Ebert T. Variability of duration of actionof neuromuscular blocking drugs in elderly patients. ActaAnaesthesiol Scand 2005;49:312-5.
7. Adamus M. Influence of age on the pharmacodynamic parametersof cisatracurium, rocuronium and vecuronium in males during totalintravenous anaesthesia - A prospective study. [Article in Czechwith English abstract]. Anest intenziv Med 2010;21:78-84.
8. Booij LHDJ, Drobnik L. Variability in the effect of muscle relaxants. Factors involved in the pharmacodynamic profile of neuromuscularblocking agents. Part II. Anestezjologia i Ratownictwo 2009;3:154-84.
9. ® TIVA Agilia. 2nd ed. Le GrandChemin, Brezins (France): Fresenius Vial, 2009.
10. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C,Goodale DB, Youngs EJ. The influence of age on propofol pharmacodynamics. Anesthesiology 1999;90:1502-16.
11. Gepts E, Shafer SL, Camu F, Stanski DR, Woestenborghs R, VanPeer A, Heykants JJ. Linearity of pharmacokinetics and modelestimation of sufentanil. Anesthesiology 1995;83:1194-204.
12. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J.Good clinical research practice in pharmacodynamicstudies of neuromuscular blocking agents II: theStockholm revision. Acta Anaesthesiol Scand 2007;51:789-808.
13. Donati F. Onset of action of relaxants. Can J Anaesth 1988;35:S52-8.
14. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring andpostoperative residual curarisation: a meta-analysis. Br J Anaesth 2007;98:302-16.
15. Adamus M, Bělohlávek R, Vujčíková M, Janásková E. The impactof different rocuronium doses on its pharmacodynamic profile: Aprospective study. [Article in Czech with English abstract]. Anestintenziv Med 2004;15:269-75.
16. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in thePACU after a single intubating dose of nondepolarizing musclerelaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8.
17. Murphy GS, Brull SJ. Residual neuromuscular block: lessonsunlearned. Part I: definitions, incidence, and adverse physiologiceffects of residual neuromuscular block. Anesth Analg 2010;111:120-8.
18. Viby-Mogensen J, Claudius C. Evidence-based management ofneuromuscular block. Anesth Analg 2010;111:1-2.
19. Donati F. Neuromuscular monitoring: what evidence do we needto be convinced? Anesth Analg 2010;111:6-8.
20. Eriksson LI, Sundman E, Olsson R, Nilsson L, Witt H, Ekbery O,Kuylenstierna R. Functional assessment of the pharynx at rest andduring swallowing in partially paralyzed humans. Anesthesiology 1997;87:1035-43.
21. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT, Kristel JJ. Residual neuromuscular block is a riskfactor for postoperative pulmonary complications. A prospective,randomised, and blinded study of postoperative pulmonary complicationsafter atracurium, vecuronium and pancuronium. ActaAnaesthesiol Scand 1997;41:1095-103.
22. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, AvramMJ, Vender JS. Residual neuromuscular blockade and criticalrespiratory events in the postanesthesia care unit. Anesth Analg 2008;107:130-7.
23. Sauer M, Stahn A, Soltesz S, Noeldge-Schomburg G, Mencke T. The influence of residual neuromuscular block on the incidenceof critical respiratory events. A randomised, prospective, placebocontrolledtrial. Eur J Anaesthesiol 2011 [Epub ahead of print]. Doi: 10.1097/EJA.0b013e328345cd11.
24. Naguib M, Brull SJ. Sugammadex: a novel selective relaxant bindingagent. Expert Rev Clin Pharmacol 2009;2:37-53.
25. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex,a selective relaxant binding agent. Anesthesiology 2007;106:283-8.
26. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscularblock: current practice. Anaesthesia 2009;64(Suppl1):22-30.
27. Miller RD, Ward TA. Monitoring and pharmacologic reversal ofa nondepolarizing neuromuscular blockade should be routine. Anesth Analg 2010;111:3-5.
28. Caldwell J E. Clinical limitations of acetylcholinesterase antagonists. J Crit Care 2009;24:21-8.
29. Kopman AF. Neostigmine versus sugammadex: which, when, andhow much? Anesthesiology 2010;113:1010-1.
30. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences indrug effects: implications for anesthesiologists. Acta AnaesthesiolScand 2003;47:241-59.
31. Soldin OP, Mattison DR. Sex differences in pharmacokinetics andpharmacodynamics. Clin Pharmacokinet 2009;48:143-57.
32. Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Prospectiveuse of population pharmacokinetics/pharmacodynamics in the developmentof cisatracurium. Pharm Res 1997;14:91-7.
33. Naguib M, Lien AC. Pharmacology of Muscle Relaxants and TheirAntagonists. In: Miller RD (editor). Miller's Anesthesia. 7th ed. Philadelphia: Churchill-Livingstone, Elsevier; 2010, p. 897.
34. Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, DonatiF. Pharmacodynamic behaviour of rocuronium in the elderly. CanJ Anaesth 1993;40:127-32.
35. Lien AC. Nondepolarizing Neuromuscular Blocking Agents in theElderly: Dosing Paradigms Revisited. Book of Proceedings from the Congress: Perioperative Care for the Geriatric Patient. Prague, June 14-16, 2009.
36. Sieber FE, Pauldine R. Geriatric Anesthesia. In: Miller RD (editor). Miller's Anesthesia. 7th ed. Philadelphia: Churchill-Livingstone,Elsevier 2010, p. 2271.
37. Adamus M, Konupcikova K, Wanek T, Hrabalek L. Influence ofage and gender on the pharmacodynamic parameters of rocuroniumduring total intravenous anaesthesia. Eur J Anaesthesiol 2011;28(S48): 9AP2-4,131.